中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

20 records (took 0.017 seconds)

    INHIBITION OF GLIADIN PEPTIDES
    1.
    发明申请
    INHIBITION OF GLIADIN PEPTIDES 审中-公开
    谷氨酸肽的抑制作用

    公开(公告)号：WO2009137572A3

    公开(公告)日：2010-03-04

    申请号：PCT/US2009042973

    申请日：2009-05-06

    Applicant: ALBA THERAPEUTICS CORP ,  ALKAN SEFIK ,  TAMIZ AMIR ,  KITCHENS KELLY MARIE ,  DURAI MALARVIZHI ,  POLOSO NEIL ,  CARRASCO ROSA A

    Inventor： ALKAN SEFIK ,  TAMIZ AMIR ,  KITCHENS KELLY MARIE ,  DURAI MALARVIZHI ,  POLOSO NEIL ,  CARRASCO ROSA A

    IPC: A61K38/04 ,  A61K38/00

    CPC classification number: C07K7/06 ,  A61K38/00 ,  A61K38/06 ,  A61K38/07 ,  A61K38/08 ,  A61K45/06 ,  C07K5/0804 ,  C07K5/0806 ,  C07K5/0808 ,  C07K5/081 ,  C07K5/0812 ,  C07K5/0815 ,  C07K5/0817 ,  C07K5/0819 ,  C07K5/0821 ,  C07K5/1008 ,  C07K5/101

    Abstract: Novel compounds and methods for the inhibition of biological barrier permeability and for the inhibition of peptide translocation across biological barriers are identified. Assays for determining modulators of biological barrier permeability and for peptide translocation across biological barriers are provided. Methods for treating diseases relating to aberrant biological barrier permeability and peptide translocation across biological barriers are provided. Such diseases include celiac disease, necrotizing enterocolitis, diabetes, cancer, inflammatory bowel diseases, asthma, COPD, excessive or undesirable immune response, gluten sensitivity, gluten allergy, food allergy, rheumatoid arthritis, multiple sclerosis, immune-mediated or type 1 diabetes mellitus, systemic lupus erythematosus, psoriasis, scleroderma and autoimmune thyroid diseases.

    Abstract translation: 鉴定了新型化合物和抑制生物屏障渗透性和抑制跨越生物屏障的肽易位的方法。 提供了用于确定生物屏障渗透性调节剂和穿过生物屏障的肽易位的测定。 提供了治疗与生物屏障渗透性异常有关的疾病和跨越生物屏障的肽易位的方法。 这些疾病包括乳糜泻，坏死性小肠结肠炎，糖尿病，癌症，炎性肠病，哮喘，COPD，过度或不良免疫反应，麸质敏感性，麸质过敏，食物过敏，类风湿性关节炎，多发性硬化，免疫介导或1型糖尿病 ，系统性红斑狼疮，牛皮癣，硬皮病和自身免疫性甲状腺疾病。

    NOVEL PEPTIDES THAT ENHANCE TIGHT JUNCTION PERMEABILITY
    2.
    发明申请
    NOVEL PEPTIDES THAT ENHANCE TIGHT JUNCTION PERMEABILITY 审中-公开
    提高紧密透气性的新型胶囊

    公开(公告)号：WO2009015382A3

    公开(公告)日：2009-04-23

    申请号：PCT/US2008071321

    申请日：2008-07-28

    Applicant: ALBA THERAPEUTICS CORP ,  TAMIZ AMIR ,  LI MIN

    Inventor： TAMIZ AMIR ,  LI MIN

    IPC: C07K5/00

    CPC classification number: C07K7/06 ,  A61K38/00 ,  C07K14/28

    Abstract: The present invention provides novel peptides that facilitate the opening of mammalian tight junctions, i.e. tight junction agonists. The present invention also provides methods for the treatment of disease by administering to a subject suffering from the disease a composition comprising a peptide tight junction agonist of the invention in combination with a therapeutically effective amount of an active agent.

    Abstract translation: 本发明提供了促进哺乳动物紧密连接的开放的新型肽，即紧密连接的激动剂。 本发明还提供了通过向患有该疾病的受试者施用包含本发明的肽紧密连接激动剂与治疗有效量的活性剂的组合来治疗疾病的方法。

    USE OF TIGHT JUNCTION ANTAGONISTS TO TREAT INFLAMMATORY BOWEL DISEASE
    3.
    发明申请
    USE OF TIGHT JUNCTION ANTAGONISTS TO TREAT INFLAMMATORY BOWEL DISEASE 审中-公开
    使用紧密连接的拮抗剂治疗炎症性皮肤疾病

    公开(公告)号：WO2008043107A3

    公开(公告)日：2009-04-09

    申请号：PCT/US2007080828

    申请日：2007-10-09

    Applicant: ALBA THERAPEUTICS CORP ,  PATERSON BLAKE ,  TAMIZ AMIR ,  PANDEY NIRANJAN

    Inventor： PATERSON BLAKE ,  TAMIZ AMIR ,  PANDEY NIRANJAN

    IPC: A61K38/08

    CPC classification number: A61K38/08 ,  A61K31/56 ,  A61K45/06 ,  C07K7/06

    Abstract: The present invention provides materials and methods for the treatment of inflammatory bowel disease (e.g., Crohn's disease and ulcerative colitis). Materials of the invention may include compositions comprising one or more tight junction antagonists and optionally one or more therapeutic agents. Methods of the invention may comprise treating a subject in need thereof with a composition comprising one or more tight junction antagonists and, optionally one or more therapeutic agents.

    Abstract translation: 本发明提供了治疗炎症性肠病（例如克罗恩病和溃疡性结肠炎）的材料和方法。 本发明的材料可以包括包含一种或多种紧密连接拮抗剂和任选的一种或多种治疗剂的组合物。 本发明的方法可以包括用包含一种或多种紧密连接拮抗剂和任选的一种或多种治疗剂的组合物治疗有需要的受试者。

    NOVEL PEPTIDES THAT INHIBIT THE OPENING OF MAMMALIAN TIGHT JUNCTIONS
    4.
    发明申请
    NOVEL PEPTIDES THAT INHIBIT THE OPENING OF MAMMALIAN TIGHT JUNCTIONS 审中-公开
    抑制MAMMALIAN TIGHT JUNCTIONS开放的新型蛋白质

    公开(公告)号：WO2008154493A3

    公开(公告)日：2009-02-19

    申请号：PCT/US2008066327

    申请日：2008-06-09

    Applicant: ALBA THERAPEUTICS CORP ,  TAMIZ AMIR ,  LI MIN

    Inventor： TAMIZ AMIR ,  LI MIN

    IPC: C07K17/00

    CPC classification number: C07K7/06 ,  A61K38/00

    Abstract: The present invention provides.novel peptides that inhibit and/or reduce the opening of mammalian tight junctions, i.e. tight junction antagonists. The present invention also provides methods for the treatment of excessive or undesirable permeability of a tissue by administering to a subject suffering from such a condition a composition comprising a peptide tight junction antagonist of the invention.

    Abstract translation: 本发明提供抑制和/或减少哺乳动物紧密连接的开放的新型肽，即紧密连接的拮抗剂。 本发明还提供了通过向患有这种病症的受试者施用包含本发明的肽紧密连接拮抗剂的组合物来治疗组织过度或不期望的渗透性的方法。

    FORMULATIONS FOR A TIGHT JUNCTION EFFECTOR
    6.
    发明申请
    FORMULATIONS FOR A TIGHT JUNCTION EFFECTOR 审中-公开
    紧密连接效应的配方

    公开(公告)号：WO2007095092A3

    公开(公告)日：2008-09-12

    申请号：PCT/US2007003486

    申请日：2007-02-09

    Applicant: ALBA THERAPEUTICS CORP ,  PATERSON BLAKE ,  GINSKI MARK J PH D

    Inventor： PATERSON BLAKE ,  GINSKI MARK J PH D

    IPC: A01N37/18

    CPC classification number: A61K38/08 ,  A61K9/009 ,  A61K9/14 ,  A61K9/1635 ,  A61K9/1652 ,  A61K9/1676 ,  A61K9/20 ,  A61K9/4808 ,  A61K9/5026 ,  A61K9/5036 ,  A61K9/5042 ,  A61K9/5047 ,  A61K9/5078 ,  A61K31/175 ,  A61K31/426 ,  A61K38/00

    Abstract: Enteric compositions comprising one or more tight junction agonists and/or one or more tight junction antagonists are provided. Compositions of the invention may comprise a delayed-release coating disposed over a tight junction agonist and/or tight junction antagonist layer which may be disposed over an inert core. Delayed-release coatings may be substantially stable in gastric fluid and substantially unstable in intestinal fluid, thus providing for substantial release of the tight junction agonist and/or antagonist from the composition in the duodenum or jejunum of the small intestine.

    Abstract translation: 提供包含一种或多种紧密结合激动剂和/或一种或多种紧密连接拮抗剂的肠溶组合物。 本发明的组合物可以包含设置在可以设置在惰性核心上的紧密连接激动剂和/或紧密连接拮抗剂层上的延迟释放涂层。 延缓释放的涂层可能在胃液中基本上是稳定的，并且在肠液中基本上不稳定，从而提供紧密连接的激动剂和/或拮抗剂从小肠的十二指肠或空肠中的组合物的显着释放。

    USE OF TIGHT JUNCTION AGONISTS TO FACILITATE PULMONARY DELIVERY OF THERAPEUTIC AGENTS
    8.
    发明申请
    USE OF TIGHT JUNCTION AGONISTS TO FACILITATE PULMONARY DELIVERY OF THERAPEUTIC AGENTS 审中-公开
    使用轻度结节性激素来促进治疗药物的脉搏递送

    公开(公告)号：WO2007124354A2

    公开(公告)日：2007-11-01

    申请号：PCT/US2007066957

    申请日：2007-04-19

    Applicant: ALBA THERAPEUTICS CORP ,  FASANO ALESSIO ,  PATERSON BLAKE

    Inventor： FASANO ALESSIO ,  PATERSON BLAKE

    IPC: A61K38/08

    CPC classification number: A61K38/08

    Abstract: The present invention provides materials and methods to facilitate the pulmonary delivery of therapeutic agents. In some embodiments, agonists of tight junctions (e.g., zonulin agonists) are used in compositions to facilitate the uptake of therapeutic agents from the pulmonary mucosa.

    Abstract translation: 本发明提供了促进治疗剂肺部递送的材料和方法。 在一些实施方案中，紧密连接的激动剂（例如泽宁激动剂）用于组合物以促进治疗剂从肺粘膜摄取。

    COMPOSITIONS AND METHODS FOR INHIBITING CYTOKINE PRODUCTION
    10.
    发明申请
    COMPOSITIONS AND METHODS FOR INHIBITING CYTOKINE PRODUCTION 审中-公开
    用于抑制细胞因子生产的组合物和方法

    公开(公告)号：WO2009110947A3

    公开(公告)日：2010-03-18

    申请号：PCT/US2008087666

    申请日：2008-12-19

    Applicant: ALBA THERAPEUTICS CORP ,  POLOSO NEIL ,  TAMIZ AMIR ,  OLIVER EDWARD ,  ALKAN SEFIK

    Inventor： POLOSO NEIL ,  TAMIZ AMIR ,  OLIVER EDWARD ,  ALKAN SEFIK

    IPC: A61K38/00 ,  A61K38/04

    CPC classification number: A61K38/08

    Abstract: Novel inhibitors of TNFa secretion are identified. Assays for determining modulators of TNFa secretion are provided. Methods for treating diseases relating to aberrant TNFa secretion are provided. Such diseases include celiac disease, diabetes, cancer, inflammatory bowel diseases, excessive or undesirable immune response, gluten sensitivity, gluten allergy, food allergy, rheumatoid arthritis, multiple sclerosis, immune-mediated or type 1 diabetes mellitus, systemic lupus erythematosus, psoriasis, scleroderma and autoimmune thyroid diseases.

    Abstract translation: 鉴定出新的TNFα分泌抑制剂。 提供了确定TNFα分泌调节剂的方法。 提供了治疗与异常TNFα分泌有关的疾病的方法。 这些疾病包括乳糜泻，糖尿病，癌症，炎症性肠病，过度或不良免疫反应，麸质敏感性，麸质过敏，食物过敏，类风湿性关节炎，多发性硬化，免疫介导或1型糖尿病，系统性红斑狼疮，银屑病， 硬皮病和自身免疫性甲状腺疾病。

Patent Agency Ranking